Roquefort Therapeutics plc (LON:ROQ)
London · Delayed Price · Currency is GBP · Price in GBX 1.400
-0.150 (-9.68%)
Jul 16, 2025, 2:00 PM BST
Roquefort Therapeutics Company Description
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer.
Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and natural killer cell-mediated anti-cancer action.
The company was incorporated in 2020 and is based in London, the United Kingdom.
Roquefort Therapeutics plc
| Country | United Kingdom |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Darrin Disley |
Contact Details
Address: 85 Great Portland Street London, W1W 7LT United Kingdom | |
| Phone | 44 20 3918 8633 |
| Website | roquefortplc.com |
Stock Details
| Ticker Symbol | ROQ |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BMDQ2T15 |
| SIC Code | 6726 |
Key Executives
| Name | Position |
|---|---|
| Stephen Paul West B.Com, CA | Executive Chairman |
| Dr. Darrin Matthew Disley O.B.E., Ph.D. | MD and Director |